MAEGEN MCGUFFIN: Open Payments
NPI 1881365864 · ABILENE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$477 in 28 payments from 11 companies in 2025. Trend: 2023 $253 · 2024 $249 · 2025 $477
Food & beverage: $477
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 12 | $193 |
| MAYNE PHARMA COMMERCIAL LLC | 3 | $64 |
| Biogen, Inc. | 2 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Novo Nordisk Inc | 1 | $23 |
| Organon LLC | 3 | $23 |
| SHIELD THERAPEUTICS INC | 1 | $23 |
| Boston Scientific Corporation | 1 | $19 |
| Amgen Inc. | 1 | $18 |
| Molnlycke Health Care US, LLC | 1 | $16 |
Products named: Veozah, ZURZUVAE, NEXPLANON, ACCRUFER, MYFEMBREE, GEMTESA, Bulkamid, EVENITY.
Industry payments across TX — which companies pay providers there.
